# Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer

> **NCT04133155** · — · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 103 (actual)

## Conditions studied

- Pancreatic Cancer
- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** nab paclitaxel plus gemcitabine

## Key facts

- **NCT ID:** NCT04133155
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-16
- **Primary completion:** 2020-01-01
- **Final completion:** 2020-02-01
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2020-03-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04133155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04133155, "Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04133155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*